Back
Halozyme Therapeutics Stock Price Chart
Sponsored
HALO
Sponsored
U.S. Government Report Alert Tuesday
Discover the Secret Loophole
Buy
72
HALO
Halozyme Therapeutics
Last Price:
57.97
Seasonality Move:
16.49%
7 Day Trial
ALL ACCESS PASS
$
7
Write This Down: Tuesday at 2 p.m. ET!
Don't Miss Our LIVE Trade- Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and HALO is experiencing slight buying pressure.
Halozyme Therapeutics Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 52.06 | Buy |
20-day SMA: | 52.41 | Buy |
50-day SMA: | 57.09 | Buy |
200-day SMA: | 47.88 | Buy |
8-day EMA: | 53.6 | Buy |
20-day EMA: | 53.47 | Buy |
50-day EMA: | 54.91 | Buy |
200-day EMA: | 50.09 | Buy |
Halozyme Therapeutics Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.73 | Sell |
Relative Strength Index (14 RSI): | 64.31 | Buy |
Chaikin Money Flow: | 522918 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (50.37 - 56.81) | Buy |
Bollinger Bands (100): | (51.47 - 59.79) | Buy |
Halozyme Therapeutics Technical Analysis
Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | Nov 4 | |
---|---|---|---|---|---|---|---|---|---|---|
Oct | Nov | |||||||||
22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | 04 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Halozyme Therapeutics Stock
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 58.46 while HALO 8-day simple moving average is 52.06, which is a Buy signal.
- The stock price of HALO is 58.46 while Halozyme Therapeutics 20-day SMA is 52.41, which makes it a Buy.
- Halozyme Therapeutics 50-day simple moving average is 57.09 while HALO share price is 58.46, making it a Buy technically.
- HALO stock price is 58.46 and Halozyme Therapeutics 200-day simple moving average is 47.88, creating a Buy signal.
HALO Technical Analysis vs Fundamental Analysis
Buy
72
Halozyme Therapeutics (HALO)
is a Buy
Is Halozyme Therapeutics a Buy or a Sell?
-
Halozyme Therapeutics stock is rated a Buy
The current Halozyme Therapeutics [HALO] share price is $58.46. The Score for HALO is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.
Halozyme Therapeutics Stock Info
Market Cap:
7.44B
Price in USD:
58.46
Share Volume:
1.89M
Halozyme Therapeutics 52-Week Range
52-Week High:
65.53
52-Week Low:
33.15
Buy
72
Halozyme Therapeutics (HALO)
is a Buy
Halozyme Therapeutics Share Price Forecast
-
What is the Halozyme Therapeutics stock price today?
The Halozyme Therapeutics stock price is 58.46 USD today. -
Will HALO stock go up or go down?
Halozyme Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Halozyme Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Halozyme Therapeutics is not overvalued.
Is Halozyme Therapeutics Stock a Buy?
- Halozyme Therapeutics share price is 58.46 while HALO 8-day exponential moving average is 53.60, which is a Buy signal.
- The stock price of HALO is 58.46 while Halozyme Therapeutics 20-day EMA is 53.47, which makes it a Buy.
- Halozyme Therapeutics 50-day exponential moving average is 54.91 while HALO share price is 58.46, making it a Buy technically.
- HALO stock price is 58.46 and Halozyme Therapeutics 200-day simple moving average is 50.09, creating a Buy signal.
Fundamental Analysis of Halozyme Therapeutics
Is Halozyme Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.35 per share, and an increase next year of $0.66 per share.
Technical Analysis of Halozyme Therapeutics
Should I short Halozyme Therapeutics stock?
- HALO Moving Average Covergence Divergence (MACD) indicator is -0.73, suggesting Halozyme Therapeutics is a Sell
- Halozyme Therapeutics Relative Strength Index (RSI) is 64.31, which suggest Halozyme Therapeutics is overbought
- The Bollinger Bands (25) for Halozyme Therapeutics is (50.37 - 56.81), which suggest Halozyme Therapeutics is a Buy
- The Bollinger Bands (100) for Halozyme Therapeutics is (51.47 - 59.79), which suggest Halozyme Therapeutics is a Buy
* Halozyme Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.